+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Drug Discovery Outsourcing Market Size, Share & Trends Analysis Report by Drug Type (Small, Large Molecules), by Therapeutic Area (Respiratory System, Immunomodulation), by Workflow, and Segment Forecasts, 2022-2030

  • PDF Icon

    Report

  • 137 Pages
  • April 2022
  • Region: Global
  • Grand View Research
  • ID: 4599556
The global drug discovery outsourcing market size is expected to reach USD 6.3 billion by 2030 at a CAGR of 7.4% over the forecast period. The COVID-19 pandemic has brought pharmaceutical companies in limelight. Drug discovery is a costly and lengthy process. This has urged pharmaceutical and biotech companies to opt for outsourcing their research activities to academic and private Contract Research Organizations (CROs). Rising partnerships between public or private entities accelerate drug discovery processes, which, in turn, increase the global demand for outsourcing services for drug discovery.



This scenario is expected to sustain post the covid implications as well. A rise in cases of chronic diseases has urged companies to develop medicines that extend life expectancy. According to the United Nations, people aged 65 years between 2015 and 2020 are expected to live an additional 17 years. Some of the key therapeutic areas where companies are actively involved in outsourcing include oncology, cardiovascular, and anti-infectives. In November 2020, AstraZeneca collaborated with 9 of the foremost oncology medical centers to expedite research in some of the hardest-to-treat cancers. The company will be funding clinical and non-clinical research proposals from members of this network.

The COVID-19 pandemic has demonstrated the value of drug discovery and development. People across the world are waiting for a vaccine while several companies are proactively involved in developing an effective vaccine to combat COVID-19. Pfizer Inc. and BioNTech SE received first approval for the vaccine following a worldwide Phase 3 trial of a potential strain to combat the virus. As for clinical trials, many of them are halted, while some are functional by adopting remote monitoring technologies. Thus, the pandemic has brought the pharmaceutical industry to center stage with drug discovery outsourcing becoming a key aspect to develop effective treatments against the virus. This is expected to boost the market revenue for the next 2 years i.e. a short-term boom, after which it shall regain its original growth curve.

Drug Discovery Outsourcing Market Report Highlights

  • In 2021, the lead identification & candidate optimization segment dominated the market. It is one of the most critical processes in drug discovery.
  • Oncology and anti-infective are projected to be among the fastest-growing segments during the forecast period.
  • Small molecules dominated the market in 2021. The segment is also projected to register a high CAGR during the forecast period. This, however, may change in the short term with higher emphasis on biologics.
  • Asia Pacific is projected to be the fastest-growing regional market during the forecast period.
  • The growth can be attributed to the government initiatives to forge alliances with U.S. pharmaceutical companies.


This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Drug Discovery Outsourcing Market

What is the estimated value of the Global Drug Discovery Outsourcing Market?

The Global Drug Discovery Outsourcing Market was estimated to be valued at $3.5 Billion in 2022.

What is the growth rate of the Global Drug Discovery Outsourcing Market?

The growth rate of the Global Drug Discovery Outsourcing Market is 7.4%, with an estimated value of $6.3 Billion by 2030.

What is the forecasted size of the Global Drug Discovery Outsourcing Market?

The Global Drug Discovery Outsourcing Market is estimated to be worth $6.3 Billion by 2030.

Who are the key companies in the Global Drug Discovery Outsourcing Market?

Key companies in the Global Drug Discovery Outsourcing Market include Albany Molecular Research Inc., Evotec, Laboratory Corporation of America Holdings, Genscript, Ppd Inc, Charles River, Wuxi Apptec, Merck & Co. Inc. and Dalton Pharma Services.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Workflow
1.1.2. Therapeutics Area
1.1.3. Drug Type
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.6.2. Volume price analysis (Model 2)
1.6.2.1. Approach 2: Volume price analysis
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
1.9.1. Objective 1:
1.9.2. Objective 2:
1.9.3. Objective 3:
1.9.4. Objective 4:
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Drug Discovery Outsourcing Market Variables, Trends & Scope
3.1. Penetration & Growth Prospect Mapping
3.2. Industry Value Chain Analysis
3.2.1. Reimbursement framework
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.3.3. Industry challenges
3.4. Drug Discovery Outsourcing Market Analysis Tools
3.4.1. Industry Analysis-Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
3.4.3. Major Deals & Strategic Alliances Analysis
3.4.4. Market Entry Strategies
Chapter 4. Drug Discovery Outsourcing Market: Workflow Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Definitions and Scope
4.3. Drug Discovery Outsourcing Market Share, 2021 & 2030
4.4. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
4.4.1. Target Identification & Screening
4.4.2. Target Validation & Functional Informatics
4.4.3. Lead Identification & Candidate Optimization
4.4.4. Preclinical Development
4.4.5. Other Associated Workflow
Chapter 5. Drug Discovery Outsourcing Market: Therapeutics Area Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Definitions and Scope
5.3. Drug Discovery Outsourcing Market Share, 2021 & 2030
5.4. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
5.4.1. Respiratory System
5.4.2. Pain and Anesthesia
5.4.3. Oncology
5.4.4. Ophthalmology
5.4.5. Hematology
5.4.6. Cardiovascular
5.4.7. Endocrine
5.4.8. Gastrointestinal
5.4.9. Immunomodulation
5.4.10. Anti-Infective
5.4.11. Central Nervous System
5.4.12. Dermatology
5.4.13. Genitourinary System
Chapter 6. Drug Discovery Outsourcing Market: Drug Type Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Definitions and Scope
6.3. Drug Discovery Outsourcing Market Share, 2021 & 2030
6.4. Market Size & Forecasts and Trend Analyses, 2017 to 2030 for the following
6.4.1. Small Molecules
6.4.2. Large Molecules (Biopharmaceuticals)
Chapter 7. Drug Discovery Outsourcing Market: Regional Estimates & Trend Analysis
7.1. Regional Market Dashboard
7.2. Regional Market Share Analysis, 2021 & 2030
7.3. Regional Market Share, 2020
7.4. North America
7.4.1. Market estimates and forecast, 2017-2030 (USD Million)
7.4.2. U.S.
7.4.2.1. Market estimates and forecast, 2017-2030 (USD Million)
7.4.3. Canada
7.4.3.1. Market estimates and forecast, 2017-2030 (USD Million)
7.5. Europe
7.5.1. Market estimates and forecast, 2017-2030 (USD Million)
7.5.2. U.K.
7.5.2.1. Market estimates and forecast, 2017-2030 (USD Million)
7.5.3. Germany
7.5.3.1. Market estimates and forecast, 2017-2030 (USD Million)
7.6. Asia Pacific
7.6.1. Market estimates and forecast, 2017-2030 (USD Million)
7.6.2. Japan
7.6.2.1. Market estimates and forecast, 2017-2030 (USD Million)
7.6.3. China
7.6.3.1. Market estimates and forecast, 2017-2030 (USD Million)
7.7. Latin America
7.7.1. Market estimates and forecast, 2017-2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Market estimates and forecast, 2017-2030 (USD Million)
7.8. MEA
7.8.1. Market estimates and forecast, 2017-2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Market estimates and forecast, 2017-2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis, by Key Market Participants
8.1.1. Albany Molecular Research Inc.
8.1.1.1. Company overview
8.1.1.2. Financial performance
8.1.1.3. Product benchmarking
8.1.1.4. Strategic initiatives
8.1.2. EVOTEC
8.1.2.1. Company overview
8.1.2.2. Financial performance
8.1.2.3. Product benchmarking
8.1.2.4. Strategic initiatives
8.1.3. Laboratory Corporation of America Holdings
8.1.3.1. Company overview
8.1.3.2. Financial performance
8.1.3.3. Product benchmarking
8.1.3.4. Strategic initiatives
8.1.4. GenScript
8.1.4.1. Company overview
8.1.4.2. Financial performance
8.1.4.3. Product benchmarking
8.1.4.4. Strategic initiatives
8.1.5. PPD Inc
8.1.5.1. Company overview
8.1.5.2. Financial performance
8.1.5.3. Product benchmarking
8.1.5.4. Strategic initiatives
8.1.6. Charles River
8.1.6.1. Company overview
8.1.6.2. Financial performance
8.1.6.3. Product benchmarking
8.1.6.4. Strategic initiatives
8.1.7. WuXi AppTec
8.1.7.1. Company overview
8.1.7.2. Financial performance
8.1.7.3. Product benchmarking
8.1.7.4. Strategic initiatives
8.1.8. Merck & Co., Inc.
8.1.8.1. Company overview
8.1.8.2. Financial performance
8.1.8.3. Product benchmarking
8.1.8.4. Strategic initiatives
8.1.9. Thermo Fisher Scientific Inc.
8.1.9.1. Company overview
8.1.9.2. Financial performance
8.1.9.3. Product benchmarking
8.1.9.4. Strategic initiatives
8.1.10. Dalton Pharma Services
8.1.10.1. Company overview
8.1.10.2. Financial performance
8.1.10.3. Product benchmarking
8.1.10.4. Strategic initiatives
8.1.11. Oncodesign
8.1.11.1. Company overview
8.1.11.2. Financial performance
8.1.11.3. Product benchmarking
8.1.11.4. Strategic initiatives
8.1.12. Jubilant Biosys
8.1.12.1. Company overview
8.1.12.2. Financial performance
8.1.12.3. Product benchmarking
8.1.12.4. Strategic initiatives
8.1.13. DiscoverX Corporation
8.1.13.1. Company overview
8.1.13.2. Financial performance
8.1.13.3. Product benchmarking
8.1.13.4. Strategic initiatives
8.1.14. QIAGEN
8.1.14.1. Company overview
8.1.14.2. Financial performance
8.1.14.3. Product benchmarking
8.1.14.4. Strategic initiatives

Companies Mentioned

  • Albany Molecular Research Inc.
  • Evotec
  • Laboratory Corporation of America Holdings
  • Genscript
  • Ppd Inc
  • Charles River
  • Wuxi Apptec
  • Merck & Co. Inc.
  • Thermo Fisher Scientific Inc.
  • Dalton Pharma Services
  • Oncodesign
  • Jubilant Biosys
  • Discoverx Corporation
  • Qiagen

Methodology

Loading
LOADING...